Metabotropic glutamate receptor 5 in bulimia nervosa.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
14 04 2020
14 04 2020
Historique:
received:
01
08
2019
accepted:
23
03
2020
entrez:
15
4
2020
pubmed:
15
4
2020
medline:
15
12
2020
Statut:
epublish
Résumé
Bulimia nervosa (BN) shares central features with substance-related and addictive disorders. The metabotropic glutamate receptor subtype 5 (mGlu5) plays an important role in addiction. Based on similarities between binge eating and substance-related and addictive disorders, we investigated mGlu5 in vivo in 15 female subjects with BN and 15 matched controls. We measured mGlu5 distribution volume ratio (DVR) with positron emission tomography (PET) using [11 C]ABP688. In BN mGlu5 DVR was higher in the anterior cingulate cortex (ACC), subgenual prefrontal cortex, and straight gyrus (p < 0.05). In BN, higher mGlu5 DVR in various brain regions, including ACC, pallidum, putamen, and caudate, positively correlated with "maturity fears" as assessed using the Eating Disorder Inventory-2 (p < 0.05). In BN and controls, smokers had globally decreased mGlu5 DVR. We present the first evidence for increased mGlu5 DVR in BN. Our findings suggest that pharmacological agents inhibiting mGlu5 might have a therapeutic potential in BN.
Identifiants
pubmed: 32286451
doi: 10.1038/s41598-020-63389-7
pii: 10.1038/s41598-020-63389-7
pmc: PMC7156702
doi:
Substances chimiques
GRM5 protein, human
0
Receptor, Metabotropic Glutamate 5
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
6374Références
Stansley, B. J. & Conn, P. J. Neuropharmacological Insight from Allosteric Modulation of mGlu Receptors. Trends. Pharmacol. Sci. 40, 240–252, https://doi.org/10.1016/j.tips.2019.02.006 (2019).
doi: 10.1016/j.tips.2019.02.006
pubmed: 30824180
pmcid: 6445545
Piers, T. et al. Translational Concepts of mGluR5 in Synaptic Diseases of the Brain. Front. Pharmacol. 3, https://doi.org/10.3389/fphar.2012.00199 (2012).
Ayala, J. E. et al. mGluR5 Positive Allosteric Modulators Facilitate both Hippocampal LTP and LTD and Enhance Spatial Learning. Neuropsychopharmacology. 34, 2057–2071, https://doi.org/10.1038/npp.2009.30 (2009).
doi: 10.1038/npp.2009.30
pubmed: 19295507
pmcid: 2884290
Joffe, M. E. et al. Mechanisms underlying prelimbic prefrontal cortex mGlu3/mGlu5-dependent plasticity and reversal learning deficits following acute stress. Neuropharmacology. 144, 19–28, https://doi.org/10.1016/j.neuropharm.2018.10.013 (2019).
doi: 10.1016/j.neuropharm.2018.10.013
pubmed: 30326237
Wijetunge, L. S., Till, S. M., Gillingwater, T. H., Ingham, C. A. & Kind, P. C. mGluR5 regulates glutamate-dependent development of the mouse somatosensory cortex. J. Neurosci. 28, 13028–13037, https://doi.org/10.1523/jneurosci.2600-08.2008 (2008).
doi: 10.1523/jneurosci.2600-08.2008
pubmed: 19052194
pmcid: 3844741
Olive, M. F. Metabotropic glutamate receptor ligands as potential therapeutics for addiction. Curr. Drug. Abuse. Rev. 2, 83–98 (2009).
doi: 10.2174/1874473710902010083
Bisaga, A., Danysz, W. & Foltin, R. W. Antagonism of glutamatergic NMDA and mGluR5 receptors decreases consumption of food in baboon model of binge-eating disorder. Eur. Neuropsychopharmacol. 18, 794–802, https://doi.org/10.1016/j.euroneuro.2008.05.004 (2008).
doi: 10.1016/j.euroneuro.2008.05.004
pubmed: 18573641
pmcid: 2591926
Mihov, Y. & Hasler, G. Negative Allosteric Modulators of Metabotropic Glutamate Receptors Subtype 5 in Addiction: a Therapeutic Window. Int. J. Neuropsychopharmacol. 19, https://doi.org/10.1093/ijnp/pyw002 (2016).
Kalivas, P. W. The glutamate homeostasis hypothesis of addiction. Nat. Rev. Neurosci. 10, 561–572, https://doi.org/10.1038/nrn2515 (2009).
doi: 10.1038/nrn2515
pubmed: 19571793
Markou, A. Metabotropic glutamate receptor antagonists: novel therapeutics for nicotine dependence and depression? Biol. Psychiatry. 61, 17–22, https://doi.org/10.1016/j.biopsych.2006.03.053 (2007).
doi: 10.1016/j.biopsych.2006.03.053
pubmed: 16876138
Pomierny-Chamiolo, L. et al. Metabotropic glutamatergic receptors and their ligands in drug addiction. Pharmacol. Ther. 142, 281–305, https://doi.org/10.1016/j.pharmthera.2013.12.012 (2014).
doi: 10.1016/j.pharmthera.2013.12.012
pubmed: 24362085
Smith, D. G. & Robbins, T. W. The neurobiological underpinnings of obesity and binge eating: a rationale for adopting the food addiction model. Biol. Psychiatry. 73, 804–810, https://doi.org/10.1016/j.biopsych.2012.08.026 (2013).
doi: 10.1016/j.biopsych.2012.08.026
pubmed: 23098895
Frank, G. K. Altered brain reward circuits in eating disorders: chicken or egg? Curr. Psychiatry Rep. 15, 396, https://doi.org/10.1007/s11920-013-0396-x (2013).
doi: 10.1007/s11920-013-0396-x
pubmed: 23963630
pmcid: 3888645
Hadad, N. A. & Knackstedt, L. A. Addicted to palatable foods: comparing the neurobiology of Bulimia Nervosa to that of drug addiction. Psychopharmacology (Berl). 231, 1897–1912, https://doi.org/10.1007/s00213-014-3461-1 (2014).
doi: 10.1007/s00213-014-3461-1
pubmed: 24500676
pmcid: 4484591
American Psychiatric Association. Diagnostic And Statistical Manual Of Mental Disorders: DSM-5. 5th edn, (American Psychiatric Association, 2013).
Akkus, F. et al. Marked global reduction in mGluR5 receptor binding in smokers and ex-smokers determined by [11C]ABP688 positron emission tomography. Proc. Natl. Acad. Sci. USA 110, 737–742, https://doi.org/10.1073/pnas.1210984110 (2013).
doi: 10.1073/pnas.1210984110
pubmed: 23248277
Akkus, F. et al. Metabotropic glutamate receptor 5 binding in male patients with alcohol use disorder. Transl. Psychiatry. 8, 17, https://doi.org/10.1038/s41398-017-0066-6 (2018).
doi: 10.1038/s41398-017-0066-6
pubmed: 29317611
pmcid: 5802584
Akkus, F. et al. Association of Long-Term Nicotine Abstinence With Normal Metabotropic Glutamate Receptor-5 Binding. Biol. Psychiatry. 79, 474–480, https://doi.org/10.1016/j.biopsych.2015.02.027 (2016).
doi: 10.1016/j.biopsych.2015.02.027
pubmed: 25861697
Hulka, L. M. et al. Smoking but not cocaine use is associated with lower cerebral metabotropic glutamate receptor 5 density in humans. Mol. Psychiatry. 19, 625–632, https://doi.org/10.1038/mp.2013.51 (2014).
doi: 10.1038/mp.2013.51
pubmed: 23628984
Milella, M. S. et al. Limbic system mGluR5 availability in cocaine dependent subjects: a high-resolution PET [(11)C]ABP688 study. Neuroimage. 98, 195–202, https://doi.org/10.1016/j.neuroimage.2014.04.061 (2014).
doi: 10.1016/j.neuroimage.2014.04.061
pubmed: 24795154
Martinez, D. et al. Imaging glutamate homeostasis in cocaine addiction with the metabotropic glutamate receptor 5 positron emission tomography radiotracer [(11)C]ABP688 and magnetic resonance spectroscopy. Biol. Psychiatry. 75, 165–171, https://doi.org/10.1016/j.biopsych.2013.06.026 (2014).
doi: 10.1016/j.biopsych.2013.06.026
pubmed: 24035345
Ceccarini, J. et al. Recovery of decreased metabotropic glutamate receptor 5 availability in abstinent alcohol-dependent patients. J. Nucl. Med., https://doi.org/10.2967/jnumed.119.228825 (2019).
Leurquin-Sterk, G. et al. Lower Limbic Metabotropic Glutamate Receptor 5 Availability in Alcohol Dependence. J. Nucl. Med. 59, 682–690, https://doi.org/10.2967/jnumed.117.199422 (2018).
doi: 10.2967/jnumed.117.199422
pubmed: 29348321
Burger, C. et al. Evaluation of a bolus/infusion protocol for 11C-ABP688, a PET tracer for mGluR5. Nucl. Med. Biol. 37, 845–851, https://doi.org/10.1016/j.nucmedbio.2010.04.107 (2010).
doi: 10.1016/j.nucmedbio.2010.04.107
pubmed: 20870160
Ametamey, S. M. et al. Radiosynthesis and preclinical evaluation of 11C-ABP688 as a probe for imaging the metabotropic glutamate receptor subtype 5. J. Nucl. Med. 47, 698–705 (2006).
pubmed: 16595505
Ametamey, S. M. et al. Human PET studies of metabotropic glutamate receptor subtype 5 with 11C-ABP688. J. Nucl. Med. 48, 247–252 (2007).
pubmed: 17268022
Akkus, F. et al. Metabotropic glutamate receptor 5 neuroimaging in schizophrenia. Schizophr. Res. 183, 95–101, https://doi.org/10.1016/j.schres.2016.11.008 (2017).
doi: 10.1016/j.schres.2016.11.008
pubmed: 27847228
Gobin, C. & Schwendt, M. The cognitive cost of reducing relapse to cocaine-seeking with mGlu5 allosteric modulators. Psychopharmacology (Berl)., https://doi.org/10.1007/s00213-019-05351-8 (2019).
Hernandez, C. M. et al. Age-Related Declines in Prefrontal Cortical Expression of Metabotropic Glutamate Receptors that Support Working Memory. eNeuro. 5, https://doi.org/10.1523/eneuro.0164-18.2018 (2018).
Olive, M. F. Cognitive effects of Group I metabotropic glutamate receptor ligands in the context of drug addiction. Eur. J. Pharmacol. 639, 47–58, https://doi.org/10.1016/j.ejphar.2010.01.029 (2010).
doi: 10.1016/j.ejphar.2010.01.029
pubmed: 20371237
pmcid: 2891107
Haass-Koffler, C. L. et al. Administration of the metabotropic glutamate receptor subtype 5 allosteric modulator GET 73 with alcohol: A translational study in rats and humans. J. Psychopharmacol. 32, 163–173, https://doi.org/10.1177/0269881117746904 (2018).
doi: 10.1177/0269881117746904
pubmed: 29361897
pmcid: 7014573
Haass-Koffler, C. L. et al. Dataset for Phase I randomized clinical trial for safety and tolerability of GET 73 in single and repeated ascending doses including preliminary pharmacokinetic parameters. Data Brief. 15, 407–413, https://doi.org/10.1016/j.dib.2017.09.018 (2017).
doi: 10.1016/j.dib.2017.09.018
pubmed: 29214202
pmcid: 5712048
Haas, L. T. et al. Silent Allosteric Modulation of mGluR5 Maintains Glutamate Signaling while Rescuing Alzheimer’s Mouse Phenotypes. Cell Rep. 20, 76–88, https://doi.org/10.1016/j.celrep.2017.06.023 (2017).
doi: 10.1016/j.celrep.2017.06.023
pubmed: 28683325
pmcid: 5547898
Akkus, F. et al. Metabotropic glutamate receptor 5 binding in patients with obsessive-compulsive disorder. Int. J. Neuropsychopharmacol. 17, 1915–1922, https://doi.org/10.1017/s1461145714000716 (2014).
doi: 10.1017/s1461145714000716
pubmed: 24833114
Deschwanden, A. et al. Reduced metabotropic glutamate receptor 5 density in major depression determined by [(11)C]ABP688 PET and postmortem study. Am. J. Psychiatry. 168, 727–734, https://doi.org/10.1176/appi.ajp.2011.09111607 (2011).
doi: 10.1176/appi.ajp.2011.09111607
pubmed: 21498461
pmcid: 3129412
Abdallah, C. G. et al. Metabotropic Glutamate Receptor 5 and Glutamate Involvement in Major Depressive Disorder: A Multimodal Imaging Study. Biol. Psychiatry. Cogn. Neurosci. Neuroimaging. 2, 449–456, https://doi.org/10.1016/j.bpsc.2017.03.019 (2017).
doi: 10.1016/j.bpsc.2017.03.019
pubmed: 28993818
pmcid: 5630181
Muller Herde, A. et al. Chronic Nicotine Exposure Alters Metabotropic Glutamate Receptor 5: Longitudinal PET Study and Behavioural Assessment in Rats. Neurotox. Res., https://doi.org/10.1007/s12640-019-00055-5 (2019).
de Laat, B. et al. Glutamatergic Biomarkers for Cocaine Addiction: A Longitudinal Study Using MR Spectroscopy and mGluR5 PET in Self-Administering Rats. J. Nucl. Med. 59, 952–959, https://doi.org/10.2967/jnumed.117.202614 (2018).
doi: 10.2967/jnumed.117.202614
pubmed: 29496988
de Laat, B. et al. Effects of alcohol exposure on the glutamatergic system: a combined longitudinal (18) F-FPEB and (1) H-MRS study in rats. Addict. Biol. 24, 696–706, https://doi.org/10.1111/adb.12635 (2019).
doi: 10.1111/adb.12635
pubmed: 29790622
Kolling, N., Behrens, T., Wittmann, M. K. & Rushworth, M. Multiple signals in anterior cingulate cortex. Curr. Opin. Neurobiol. 37, 36–43, https://doi.org/10.1016/j.conb.2015.12.007 (2016).
doi: 10.1016/j.conb.2015.12.007
pubmed: 26774693
pmcid: 4863523
Noonan, M. P., Kolling, N., Walton, M. E. & Rushworth, M. F. Re-evaluating the role of the orbitofrontal cortex in reward and reinforcement. Eur. J. Neurosci. 35, 997–1010, https://doi.org/10.1111/j.1460-9568.2012.08023.x (2012).
doi: 10.1111/j.1460-9568.2012.08023.x
pubmed: 22487031
Rushworth, M. F., Kolling, N., Sallet, J. & Mars, R. B. Valuation and decision-making in frontal cortex: one or many serial or parallel systems? Curr. Opin. Neurobiol. 22, 946–955, https://doi.org/10.1016/j.conb.2012.04.011 (2012).
doi: 10.1016/j.conb.2012.04.011
pubmed: 22572389
Rolls, E. T. T. olfactory, and food reward value processing in the brain. Prog. Neurobiol. 127–128, 64–90, https://doi.org/10.1016/j.pneurobio.2015.03.002 (2015).
doi: 10.1016/j.pneurobio.2015.03.002
pubmed: 25812933
Kringelbach, M. L., O’Doherty, J., Rolls, E. T. & Andrews, C. Activation of the human orbitofrontal cortex to a liquid food stimulus is correlated with its subjective pleasantness. Cereb. Cortex. 13, 1064–1071 (2003).
doi: 10.1093/cercor/13.10.1064
Suzuki, S., Cross, L. & O’Doherty, J. P. Elucidating the underlying components of food valuation in the human orbitofrontal cortex. Nat. Neurosci. 20, 1780–1786, https://doi.org/10.1038/s41593-017-0008-x (2017).
doi: 10.1038/s41593-017-0008-x
pubmed: 29184201
pmcid: 6214455
Esterlis, I., Holmes, S. E., Sharma, P., Krystal, J. H. & DeLorenzo, C. Metabotropic Glutamatergic Receptor 5 and Stress Disorders: Knowledge Gained From Receptor Imaging Studies. Biol. Psychiatry. 84, 95–105, https://doi.org/10.1016/j.biopsych.2017.08.025 (2018).
doi: 10.1016/j.biopsych.2017.08.025
pubmed: 29100629
Nowak, G. et al. Prolonged administration of antidepressant drugs leads to increased binding of [(3)H]MPEP to mGlu5 receptors. Neuropharmacology. 84, 46–51, https://doi.org/10.1016/j.neuropharm.2014.04.016 (2014).
doi: 10.1016/j.neuropharm.2014.04.016
pubmed: 24796254
Smialowska, M. et al. Effect of chronic imipramine or electroconvulsive shock on the expression of mGluR1a and mGluR5a immunoreactivity in rat brain hippocampus. Neuropharmacology. 42, 1016–1023, https://doi.org/10.1016/s0028-3908(02)00062-x (2002).
doi: 10.1016/s0028-3908(02)00062-x
pubmed: 12128002
Esterlis, I. et al. Ketamine-induced reduction in mGluR5 availability is associated with an antidepressant response: an [(11)C]ABP688 and PET imaging study in depression. Mol. Psychiatry. 23, 824–832, https://doi.org/10.1038/mp.2017.58 (2018).
doi: 10.1038/mp.2017.58
pubmed: 28397841
Fairburn, C. G. & Beglin, S. J. Assessment of eating disorders: interview or self-report questionnaire? Int. J. Eat. Disord. 16, 363–370 (1994).
pubmed: 7866415
Hilbert, A., Tuschen-Caffier, B., Karwautz, A., Niederhofer, H. & Munsch, S. Eating Disorder Examination-Questionnaire: Psychometric properties of the German version. Diagnostica. 53, pp, https://doi.org/10.1026/0012-1924.53.3.144 (2007).
Thiel, A. et al. A German version of the Eating Disorder Inventory EDI-2. Psychother. Psychosom. Med. Psychol. 47, 365–376 (1997).
pubmed: 9411465
Esterlis, I., Holmes, S. E., Sharma, P., Krystal, J. H. & DeLorenzo, C. Metabotropic Glutamatergic Receptor 5 and Stress Disorders: Knowledge Gained From Receptor Imaging Studies. Biol. Psychiatry., https://doi.org/10.1016/j.biopsych.2017.08.025 (2017).
Holmes, S. E. et al. Altered metabotropic glutamate receptor 5 markers in PTSD: In vivo and postmortem evidence. Proc. Natl. Acad. Sci. USA 114, 8390–8395, https://doi.org/10.1073/pnas.1701749114 (2017).
doi: 10.1073/pnas.1701749114
pubmed: 28716937
Grob, S. et al. Dopamine-related deficit in reward learning after catecholamine depletion in unmedicated, remitted subjects with bulimia nervosa. Neuropsychopharmacology. 37, 1945–1952, https://doi.org/10.1038/npp.2012.41 (2012).
doi: 10.1038/npp.2012.41
pubmed: 22491353
pmcid: 3376326
Grob, S. et al. Behavioral responses to catecholamine depletion in unmedicated, remitted subjects with bulimia nervosa and healthy subjects. Biol. Psychiatry. 77, 661–667, https://doi.org/10.1016/j.biopsych.2013.09.013 (2015).
doi: 10.1016/j.biopsych.2013.09.013
pubmed: 24209774
Mueller, S. V., Mihov, Y., Federspiel, A., Wiest, R. & Hasler, G. Neural response to catecholamine depletion in remitted bulimia nervosa: Relation to depression and relapse. Eur. Neuropsychopharmacol. 27, 633–646, https://doi.org/10.1016/j.euroneuro.2017.04.002 (2017).
doi: 10.1016/j.euroneuro.2017.04.002
pubmed: 28502528
Mueller, S. V. et al. Neural Correlates of Impaired Reward-Effort Integration in Remitted Bulimia Nervosa. Neuropsychopharmacology. 43, 868–876, https://doi.org/10.1038/npp.2017.277 (2018).
doi: 10.1038/npp.2017.277
pubmed: 29105662
Frank, G. K. The Perfect Storm - A Bio-Psycho-Social Risk Model for Developing and Maintaining Eating Disorders. Front. Behav. Neurosci. 10, 44, https://doi.org/10.3389/fnbeh.2016.00044 (2016).
doi: 10.3389/fnbeh.2016.00044
pubmed: 27014006
pmcid: 4785136
Sephton, S. M. et al. Preclinical evaluation and test-retest studies of [(18)F]PSS232, a novel radioligand for targeting metabotropic glutamate receptor 5 (mGlu5). Eur. J. Nucl. Med. Mol. Imaging. 42, 128–137, https://doi.org/10.1007/s00259-014-2883-7 (2015).
doi: 10.1007/s00259-014-2883-7
pubmed: 25139517
Wong, D. F. et al. 18F-FPEB, a PET radiopharmaceutical for quantifying metabotropic glutamate 5 receptors: a first-in-human study of radiochemical safety, biokinetics, and radiation dosimetry. J Nucl Med. 54, 388–396, https://doi.org/10.2967/jnumed.112.107995 (2013).
doi: 10.2967/jnumed.112.107995
pubmed: 23404089
First, M., Spitzer, R. L., Gibbon, M. L. & Williams, J. Structured Clinical Interview For DSM-IV-TR Axis I Disorders, Research Version, Non-Patient Edition. (2002).
Beck, A. T., Epstein, N., Brown, G. & Steer, R. A. An inventory for measuring clinical anxiety: psychometric properties. J. Consult. Clin. Psychol. 56, 893–897 (1988).
doi: 10.1037/0022-006X.56.6.893
Beck, A. T., Ward, C. H., Mendelson, M., Mock, J. & Erbaugh, J. An inventory for measuring depression. Arch. Gen. Psychiatry. 4, 561–571 (1961).
doi: 10.1001/archpsyc.1961.01710120031004
Garner, D. M. Eating Disorder Inventory-2: Professional Manual. (Psychological Assessment Resources, 1991).
Bollini, P., Pampallona, S., Tibaldi, G., Kupelnick, B. & Munizza, C. Effectiveness of antidepressants. Meta-analysis of dose-effect relationships in randomised clinical trials. Br. J. Psychiatry. 174, 297–303 (1999).
doi: 10.1192/bjp.174.4.297